The current study aimed to assess whether these educational activities, along with increasing body of evidence supporting the safety and effectiveness of new anti-obesity drugs, particularly glucagon-like peptide 1 (GLP1) receptor agonists, had an impact on practices and attitudes of Italian endocrinologists regarding care of people with obesity. The gene discussed is GLP1R; the disease is Obesity.